tradingkey.logo

Abbott Laboratories Says New Clinical Study Data Showcase Long-Term, Sustained Benefits Of Abbott's Volt™ Pfa System For Patients With Afib

ReutersApr 26, 2025 11:17 PM

- Abbott Laboratories ABT.N:

  • NEW CLINICAL STUDY DATA SHOWCASE LONG-TERM, SUSTAINED BENEFITS OF ABBOTT'S VOLT™ PFA SYSTEM FOR PATIENTS WITH AFIB

  • ABBOTT LABORATORIES - VOLT PFA SYSTEM SHOWS STRONG 12-MONTH RESULTS

  • ABBOTT LABORATORIES - 83.5% PAF AND 58.1% PERSAF PATIENTS ARRHYTHMIA-FREE AFTER 12 MONTHS

  • ABBOTT LABORATORIES - ONLY 2.7% EXPERIENCED SAFETY ENDPOINT EVENT AFTER 12 MONTHS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI